Chemical inhibitors of ATF-6 can exert their inhibitory effects through various mechanisms that disrupt the protein's activation and function within the cellular environment. AEBSF, a serine protease inhibitor, prevents the proteolytic activation of ATF-6, which is a necessary step for its function in response to endoplasmic reticulum (ER) stress. Similarly, E-64, by irreversibly inhibiting cysteine proteases, disrupts the proteolytic processing of ATF-6, an event crucial for its activation. ALLN, or Calpain Inhibitor I, targets calpains and the proteasomal degradation pathways, both of which are involved in the cleavage and regulation of ATF-6, leading to its inhibition. MG-132 further impedes ATF-6 by inhibiting the proteasome, which is responsible for degrading misfolded proteins and could also degrade ATF-6's cytoplasmic domain, reducing its transcriptional activity.
Kifunensine and Tunicamycin disrupt glycosylation processes; since ATF-6 requires proper glycosylation for its function, interference from these chemicals results in its inhibition. Brefeldin A disrupts ER-to-Golgi trafficking, a pathway essential for ATF-6 to undergo activation. This disruption prevents ATF-6 from reaching the Golgi where it is processed into its active form. Thapsigargin, by inhibiting SERCA, induces ER stress, which can lead to ATF-6 degradation before it becomes functionally active. Salubrinal and Guanabenz extend the phosphorylation state of eIF2α, a modification that is required for ATF-6 activation during ER stress; therefore, their action results in the inhibition of ATF-6. Sephin1 also targets the phosphorylation of eIF2α, ensuring that ATF-6 remains inactive by preventing the attenuation of stress signals necessary for its activation. Lastly, ISRIB inhibits the activation of ATF-6 by reversing the effects of eIF2α phosphorylation, a critical step for ATF-6 function, thereby maintaining ATF-6 in an inactive state. Each of these chemicals acts on specific pathways or cellular processes that are intimately connected to the proper functioning of ATF-6, resulting in its inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AEBSF hydrochloride | 30827-99-7 | sc-202041 sc-202041A sc-202041B sc-202041C sc-202041D sc-202041E | 50 mg 100 mg 5 g 10 g 25 g 100 g | $65.00 $122.00 $428.00 $851.00 $1873.00 $4994.00 | 33 | |
AEBSF inhibits serine proteases, which are necessary for ATF-6 activation by proteolytic cleavage during the unfolded protein response. By inhibiting these proteases, AEBSF prevents the activation of ATF-6. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is an irreversible cysteine protease inhibitor; by inhibiting these proteases, it can prevent the cleavage and activation of ATF-6, which requires processing by cysteine proteases. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that can prevent the degradation of ATF-6's cytoplasmic domain, impeding its transcriptional activity. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase inhibitor, which affects the glycosylation of proteins. Proper glycosylation is necessary for ATF-6 to function properly, thus inhibition can lead to ATF-6 functional inhibition. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts ER-to-Golgi trafficking, which is essential for ATF-6 to reach locations where it gets activated through proteolytic cleavage. This results in the functional inhibition of ATF-6. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which is critical for ATF-6 to maintain its proper function and stability, hence its inhibition can functionally inhibit ATF-6. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to ER stress; sustained ER stress can lead to ATF-6 degradation and therefore functional inhibition. | ||||||
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Salubrinal selectively inhibits dephosphorylation of eIF2α. Phosphorylated eIF2α is implicated in ATF-6 activation, thus salubrinal can prevent ATF-6 from being functionally active. | ||||||
Guanabenz acetate | 23256-50-0 | sc-203590 sc-203590A sc-203590B sc-203590C sc-203590D | 100 mg 500 mg 1 g 10 g 25 g | $102.00 $468.00 $832.00 $4162.00 $7283.00 | 2 | |
Guanabenz can selectively inhibit the dephosphorylation of eIF2α similar to Salubrinal. This will inhibit ATF-6 activation by preventing its translocation to the Golgi. | ||||||
Sephin1 | 13098-73-2 | sc-507502 | 5 mg | $578.00 | ||
Sephin1 prolongs the eIF2α phosphorylation response. Persistently phosphorylated eIF2α can lead to inhibition of ATF-6 activation due to failure to induce proper UPR signaling. | ||||||